ArticlePeerJ2023

Sema4D silencing increases the sensitivity of nivolumab to B16-F10 resistant melanoma via inhibiting the PI3K/AKT signaling pathway.

Zhuo Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.